课题基金 / 基金详情

Development and commercialisation of a novel treatment for multiple sclerosis

Development and commercialisation of a novel treatment for multiple sclerosis
多发性硬化症新疗法的开发和商业化
批准号：
335098
负责人：
Liu Fang
金额：
$21.79万
依托单位：
Centre for Addiction and Mental Health (Toronto)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2015
资助国家：
加拿大
项目状态：
已结题
起止时间：
2015-09-01 至 2016-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=335098&lang=en
关键词：
Gapdh Glutamate Receptors Interfering Peptide Multiple Sclerosis Neurotoxicity Novel Drug Protein-Protein Interaction

项目摘要

项目成果

Liu Fang的其他基金

相似基金

相关文献

中文摘要
翻译
多发性硬化症的治疗需要改进，因为目前的方法不能完全控制症状，也不能从本质上改变疾病的结果。大多数关于多发性硬化症的研究都集中在免疫系统上，目前的治疗方法还很有限
英文摘要
Treatments for multiple sclerosis need improvement, since current approaches offer incomplete symptom control and do not substantially alter disease outcomes. Most research into multiple sclerosis has focused on the immune system and current treatments ar
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating a novel pathway regulating dendritic spine pruning in Fmr1 knock out mice
The role of FK506 binding protein 51 in the regulation of glucocorticoid receptor signaling
The role of FK506 binding protein 51 in the regulation of glucocorticoid receptor signaling
Application Development Workshop for the Team Grant: GACD Mental Health - Canada-China program
海外基金